Search research articles
Contact Us
Filters
Showing results (41-50 of 681) with videos related to
Page
of 69
Sort By:
Cancer Discovery
|
June 3, 2021
Inhibiting the Inhibitors of Apoptosis: When Two Targets Are Better Than One
Karilyn T M Larkin, John C Byrd
Seminars in Oncology
|
April 18, 2006
Epigenetics in chronic lymphocytic leukemia
Aparna Raval, John C Byrd, Christoph Plass
Cancers
|
December 11, 2022
Natural Killer Cells in Chronic Lymphocytic Leukemia: Functional Impairment and Therapeutic Potential
Max Yano, John C Byrd, Natarajan Muthusamy
Blood
|
July 22, 2004
Adult Burkitt leukemia and lymphoma
Kristie A Blum, Gerard Lozanski, John C Byrd
Blood
|
March 7, 2015
Response: Additional data needed for a better understanding of the potential relationship between atrial fibrillation and ibrutinib
John C Byrd, Peter Hillmen, Danelle F James
Seminars in Oncology
|
April 5, 2016
Cyclin-dependent kinase inhibitors for the treatment of chronic lymphocytic leukemia
James S Blachly, John C Byrd, Michael Grever
Seminars in Hematology
|
July 23, 2014
The B-cell receptor pathway: a critical component of healthy and malignant immune biology
Yiming Zhong, John C Byrd, Jason A Dubovsky
Journal of Immunology (Baltimore, Md. : 1950)
|
February 4, 2006
Differential role for cyclic AMP response element binding protein-1 in multiple stages of B cell development, differentiation, and survival
Hui-Chen Chen, John C Byrd, Natarajan Muthusamy
Autophagy
|
February 21, 2013
Autophagy and ER stress play an essential role in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol
Emilia Mahoney, John C Byrd, Amy J Johnson
The Journal of Clinical Investigation
|
November 6, 2018
PLK1: a promising and previously unexplored target in double-hit lymphoma
Quais N Hassan, Lapo Alinari, John C Byrd
Page
of 69
Search research articles
Search
Showing results (41-50 of 681) with videos related to
Sort By:
Page
of 69
Cancer Discovery
|
June 3, 2021
Inhibiting the Inhibitors of Apoptosis: When Two Targets Are Better Than One
Karilyn T M Larkin, John C Byrd
Seminars in Oncology
|
April 18, 2006
Epigenetics in chronic lymphocytic leukemia
Aparna Raval, John C Byrd, Christoph Plass
Cancers
|
December 11, 2022
Natural Killer Cells in Chronic Lymphocytic Leukemia: Functional Impairment and Therapeutic Potential
Max Yano, John C Byrd, Natarajan Muthusamy
Blood
|
July 22, 2004
Adult Burkitt leukemia and lymphoma
Kristie A Blum, Gerard Lozanski, John C Byrd
Blood
|
March 7, 2015
Response: Additional data needed for a better understanding of the potential relationship between atrial fibrillation and ibrutinib
John C Byrd, Peter Hillmen, Danelle F James
Seminars in Oncology
|
April 5, 2016
Cyclin-dependent kinase inhibitors for the treatment of chronic lymphocytic leukemia
James S Blachly, John C Byrd, Michael Grever
Seminars in Hematology
|
July 23, 2014
The B-cell receptor pathway: a critical component of healthy and malignant immune biology
Yiming Zhong, John C Byrd, Jason A Dubovsky
Journal of Immunology (Baltimore, Md. : 1950)
|
February 4, 2006
Differential role for cyclic AMP response element binding protein-1 in multiple stages of B cell development, differentiation, and survival
Hui-Chen Chen, John C Byrd, Natarajan Muthusamy
Autophagy
|
February 21, 2013
Autophagy and ER stress play an essential role in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol
Emilia Mahoney, John C Byrd, Amy J Johnson
The Journal of Clinical Investigation
|
November 6, 2018
PLK1: a promising and previously unexplored target in double-hit lymphoma
Quais N Hassan, Lapo Alinari, John C Byrd
Page
of 69